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Abstract 
Background. In the last decades we have seen a constant growth in
the fields of science related to the use of genome-based health infor-
mation. However, there is a gap between basic science research and
the Public Health everyday practice. For a successful introduction of
genome-based technologies policy actions on the international level
are needed. This work represents the initial stage of the PHGEN II
(Public Health Genomics European Network II) project. In order to pre-
pare a base for bridging genomics and Public Health, an inventory
study of the existing legislative base dealing with controversies of
genome-based knowledge was conducted. The work results in the
mapping of the most and the least legislatively covered areas and some
preliminary conclusions about the existing gaps.
Design and Methods. The collection of the evidence-based policies
was done through the PHGEN II project. The mapping covered the
meta-level (international, European general guidelines). The expert
opinion of the partners of the project was required to reflect on and
grade the collected evidence. 
Results. An analysis of the evidence was made by the area of cover-
age: using the list of important policy areas for successful introduction
of genome-based technologies into Public Health and the Public
Health Genomics Wheel (originally Public Health Wheel developed by
Institute of Medicine).
Conclusions. Severe inequalities in coverage of important issues
of Public Health Genomics were found. The most attention was paid
to clinical utility and clinical validity of the screening and the pro-
tection of human subjects. Important areas such as trade agree-
ments, Public Health Genomics literacy, insurance issues, behav-
iour modification in response to genomics results etc. were paid
less attention to. 
For the successful adoption of new technologies on the Public
Health level the focus should be not only on the translation to clinical
practice, but the translation from bench to Public Health policy and
back. Coherent and consistent coverage of all aspects of the transla-
tion of genome based information and technologies is of outmost
importance.
IntroductionProblem statement
An exponential growth in the fields of science related to the use of
gene and genome based health information for improving the health
of the individuals can be noted. The initial boost to the fields was pro-
vided by the Human Genome project, the 13-year old initiative which
goals, among others, were to identify all genes in human DNA and
improve data analysis. Lately the focus of the research is shifting from
the highly individual level of dealing with rare genetic diseases
towards more improvements for the population in general through
inclusion of more genomic components in Public Health practice. This
leads to the development of Public Health Genetics, which later
evolved into Public Health Genomics. The Public Health Genomics is
defined as the responsible and effective translation of genome-based
knowledge and technologies into public policy and health services for
the benefit of the population health.1
Since the beginning of the decoding of the human genome the pos-
sible Ethical, Legal and Social implications were considered to be
important. The consultative bodies in the developed countries on all
levels (international, national, regional) paid a lot of attention to pro-
tection of the rights and the freedoms of individuals who undertake
the genetic test, against possible misuse of genetic data such as
genetic discrimination. The first case of genetic discrimination that
resulted in legal actions was observed in the Unites States of America
in 2010.2 Anticipation of such events resulted in 53 legal and advisory
acts published by international organisations since 1990 to 2010
(www.humgen.org/int/) which are dealing with problems of informa-
tion misuse and genetic discrimination. 
Despite of the importance of the Ethical, Legal and Social consider-
ations on genome-based information and technology development, a
broader application of these technologies in Public Health around the
world is potentially possible when the attention of the policy-makers
focuses also on other important aspects of translational process. In the
literature it is discussed that before the actual impact of these
Significance for public health
The promises on improvements made by genomics for public health have
been considerable in the last decade, however, as we see in practice only a
relatively small number of promising innovations make their way into the
health application. This can be possibly due to the ineffective mechanisms of
translation of discoveries into public policy. The relevance of the present
study roots from its ability to potentially reduce the time delay between basic
science inventions and their use in the everyday Public Health practice.
In the realm of the Public Health policy-making nowadays there is a need to
come up with a strategy that can be utilised for assessing and translating the
new knowledge offered by the genome-based information as well as facilitate
its translation into practice. And the present work can help identifying the
possible weaknesses of the present legislative approach and suggest a frame-
work to look at the policy-making in the field of Public Health Genomics.
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advances could be seen, the existing gap between gene discovery and
the application of genomic information in Public Health should be
bridged.3-5 And one of the potential ways of narrowing such gap would
be a wider use of translational research methodologies. 
When speaking about translational research the definition formulat-
ed by several National Institutes of Health (NIH) is widely used.
Translational research is the process of applying ideas, insights and dis-
coveries generated through basic scientific inquiry to the treatment or
prevention of human disease.6 The goal of such research should be
enhanced transition of the innovations from bench to bedside.7
Translational research is a continuing process and is perceived to
consist of four important steps. The first stage implies the transfer of
new understandings of disease mechanisms gained in the laboratory into
the development of new methods for diagnosis, therapy, and prevention
and their first testing in humans,8 the next step includes the translation
of results from clinical studies into everyday clinical practice and health
decision making,8 third step focuses on searching ways to move these
findings into the daily care of patient(s),9 and finally the last phase
attempts moving scientific knowledge into the public sector and thereby
changing people’s everyday lives.9
Due to the fact that sometimes for personalised genomic interven-
tions minimal clinical benefit is shown during initial steps of assess-
ment of intervention (due to rareness of the disease or too person-
alised nature of the intervention), enthusiasm of the researchers
fades. Instead, the attention is shifted to the new wave of promising
therapeutic interventions.10
In order to optimise the process of transition of the genome-based
innovation it is important to review the current approach to the organ-
isation of Public Health services and the present practice of transla-
tional research should be challenged.11
The present article aims at discussing the present policy approach
to the translation of genome-based technologies in Public Health
through identification of gaps in existing international evidence in
the field. In order to do so the overview of the list of international pol-
icy documents compiled during the mapping exercise at initial stage
of Public Health Genomics European Network II Project will be pre-
sented. The collected evidence will be analysed according to the
defined list of important areas for development of Public Health
Genomics. Since policy-making is a continuous process rather than a
pure list of policy areas, the Public Health Wheel will be used as a
benchmark, representing tasks and processes in Public Health12 in
order to systematically link genomics and Public Health. The results
of this two-step analysis will be discussed, the identified gaps in the
international policies will be mentioned, and conclusions about
future policy actions in Public Health Genomics and Public
Policymaking will be presented.Significance for Public Health 
The promises on improvements made by genomics for Public Health
have been considerable in the last decade, however, as we see in prac-
tice only a relatively small number of promising innovations make their
way into the health application. This can be possibly due to the ineffec-
tive mechanisms of translation of discoveries into public policy. The
relevance of the present study roots from its ability to potentially reduce
the time delay between basic science inventions and their use in the
everyday Public Health practice. 
In the realm of the Public Health policy-making nowadays there is a
need to come up with a strategy that can be utilised for assessing and
translating the new knowledge offered by the genome-based informa-
tion as well as facilitate its translation into practice.13 The present work
can help identifying the possible weaknesses of the present legislative
approach and suggest a framework to look at the policy-making in the
field of Public Health Genomics.
Study design and methodology
To start the process of reconsidering the vision of healthcare and ini-
tiating changes in the current Public Health approach, it is important
to conduct research on the existing best practices. Addressing these
needs, the Public Health Genomics European Network II (PHGEN II)
was initiated with support of the European Commission to develop
European Best Practice Guidelines for Quality Assurance, Provision
and Use of Genome-based Information and Technologies in 2008.
These guidelines will assist the EU Member States, Applicant and
EFTA-EEA (European Free Trade Agreement - European Economic
Area) countries with evidence-based guidance on the timely and
responsible integration of genome-based information and technologies
into healthcare for the benefit of population health. The project assem-
bles 20 associate partners and 3 collaborating partners from 14
European countries, and convenes top European scientists from differ-
ent areas linked to Public Health Genomics: Public Health, Public
Policy, Law, Medical and Basic sciences, Ethics, Health Technology
Assessment and Sociology. Eligibility criteria
In order to develop the new best-practice guidelines, the inventory of
existing evidence was needed. The decision was made within the proj-
ect to focus on policy guidelines: rules or principles that provide guid-
ance to appropriate behaviour, and thus include non-mandatory inter-
national policy documents giving suggestions rather than prescribing
actions were selected. This was agreed to due to the aim of the project
of constructing the first edition of European Best Practice Guidelines,
thus the potentially similar documents were included.
Inclusion criteria were designed in order to achieve the widest cov-
erage and to exclude inappropriate guidelines. It was agreed that the
analysis would take the meta-level, including guidelines proposed by
the international organisations or scientific and research groups. The
attention was paid to the fact that the candidate documents need to
touch important Public Health issues within the genomic sciences, to
have a wide scope covering the issue from the different angles and to
be flexible to possible future changes in the technology. The focus on
the more genome-based, not just genetic, information, used in PHGEN
II is a relatively new accomplishment, which had been previously pro-
moted in Europe during the first phase of PHGEN (2006-2008). The
guidelines adopted after January 1990 and until May 2010 were consid-
ered to be fulfilling the time-line criteria, set by the project. However, if
two or more documents dealing with the same topic were issued by the
same institution, only the latest one was included in the list of com-
piled evidence.Information sources and data collection process
The search for the documents was conducted in three directions:
expert databases, practice oriented, academic. The search process is
depicted in the Table 1.
Results
The final compilation of the existing guidelines consists of 101 docu-
ments (January 2011) covering policies regarding genetic services in
healthcare being one of the tasks of Public Health Genomics (Figure 1). Study selection
After the search for documents, a consensus-based assessment and
evaluation was done through the expert survey amongst the partners of
the PHGEN II project. The compiled list of 150 guidelines was sent to
the partners and they were asked to analyse the relevance of the docu-
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ments according to 6 categories according to their experience and the
vision of Public Health Genomics (high, high-medium, medium, medi-
um-low, low relevance and non-relevance). Each category was assigned
the numerical value from 5 to 0 (5 - high, 0 - non-relevant), inspired by
the Likert scale.14,15 Participating partners were asked to bear the def-
inition of Public Health Genomics in mind as a reference for the rele-
vance assessment: i) is the document applicable to different genomic
information and technologies; ii) does the document deal with a pres-
ent or potential Public Health issue and iii) could information provid-
ed in the document be used for the new set of European Guidelines in
PHG. After completion of the assessment form by the partners the
mean relevance was calculated. The documents which were assessed
as non-relevant by the partners were excluded from the final compila-
tion of the guidelines. In addition, partners had an option of adding the
documents they considered to be relevant. In such case the procedure
was repeated for these documents as well. Based on the input of the
experts the list was narrowed to 101 documents (Figure 2). 
Summary measures and synthesis of results
Areas of coverage of the collected documents were identified using
the list of important policy areas for successful introduction of genome-
based technologies into Public Health by Haga and Willard.16 In their
article the authors suggest dividing the important policy issues in
genome sciences in 5 main categories (research, legal, economic, edu-
cation and acceptance/implementation issues), which are later subdi-
vided (Table 2). The division and identification of the areas important
for the development of Public Health Genomics is done taking into con-
sideration the natural history of any genome application or advance
from discovery into everyday practice and the international and US pol-
icy focus regarding the genomics. The division was chosen because of
its substantial link to the policy-making process in Public Health
Genomics and the in-depth consideration of the current legislation
applicable in the field.
The assessments were collected, centrally assessed and allocated to
the areas using the majority of the votes, in case of 2 or more dominant
choices, several areas were added to the document. If the document
was dealing with one group of issues and using the methods of the
other, for instance looking at the research issues from the legal point
of view, both categories were assigned to the document. In order to
identify the gaps in a more reliable way, the mean eminence of the doc-
uments included in each area was calculated. 
Public health policy is a complicated non-linear process, thus, in
order to identify the existing policy gaps, it is important to not only
analyse the coverage of the important issues, but also to look at the
consequent processes in Public Health and its tasks. Thus it was also
decided to analyse the collected evidence in accordance with the blue-
print for Public Health Genomics, which depicts an image designed to
develop or contribute to general knowledge of the impact of human
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Table 1. Information sources and the process of evidence search.
Search step Short description Examples Search key words
Expert databases General search via internet, using search HumGen International, policy database Public Health,
mechanisms of databases of laws and of the Public Health Genomics Foundation, healthcare policy papers,
policies in healthcare the BioPortal of GRaPH-Int genomics,
(Genome-based Research and Population genetics,
Health International Network) Public Health Genomics, innovations
and Google.com in public health, new technologies,
genome-based, 
genomics of infectious diseases, 
nutrigenomics,
policy,
guidelines, 
legislation
(and their combinations)
Practice oriented Search on the websites of relevant World Health Organisation (WHO),
international organizations and authorities Pan American Health Organisation,
United Nations (UN), World Trade
Organisation (WTO), Organisation for
Economic Co/operation and Development
(OECD), European Parliament, European
Commission, World Bank, United Nations
Children’s Fund and the International
Red Cross and Red Crescent Movement
Academic Articles dealing with the topic of the JSTOR, Web of Science, PubMed, BioMed
genome-based information and Central, Science Direct, Google Scholar
technologies were scanned for and Springerlink
references to relevant international
treaties or other policy documents.
Figure 1. Division of the documents by their relevance to Public
Health Genomics (n=101). 
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genetic variation on health and disease.5 The blueprint for Public
Health Genomics has the same outline as the Public Health Wheel,
developed by the Institute of Medicine (IOM).12 The three core func-
tions of Public Health were initially identified: assessment, policy
development and assurance. Later these areas were expanded into the
10 essential Public Health tasks.17 The division of the Public Health
Genomics tasks and their description can be found in Table 3. 
The allocation of the documents according to the blueprint for Public
Health Genomics was done in the similar manner to the previous stage
of analysis concerning assessment of relevance of the documents.
On the completion of the two steps of the analysis the areas with the
least coverage were identified based on the number of documents cov-
ering each task and on the medium relevance of the documents.Analysis
We observed the following division of scope of action: 47 documents
regulate the situation in the European Union, 49 guidelines are adopt-
ed on the wider international level and represent positions of such
organisations such as the OECD, UN, WHO and others. In 6 cases coun-
try specific reports were added to the list because, despite their nation-
al focus, the text of the guidelines touched upon important issues and
was general enough to be adopted on the international level (topics
included genetics of common diseases, pharmacogenomics, tissue use
and genetic test evaluation). Forty-three documents were agreed to be
of high relevancy for the future development of the guidelines, 6 guide-
lines were considered to be of high/medium relevancy. Partners rated
42 documents out of 101 as ones of the medium relevancy, while 4 of
medium/low relevancy. 
The results of the first step of analysis (coverage of the important
areas according to S.Haga) are presented in Figure 3 (the median rel-
evance of the documents included in each criteria was assigned in
terms of colour in accordance with the legend). From the presented
chart we can see that the legal and research areas regarding genomic
sciences are quite well covered, both by the number of the documents
dealing with the respective issues and by the median relevance of the
documents. On the other hand, economic, education, acceptance as
well as implementation issues are not high on the policy agenda. The
number of the documents is significantly less and the relevance of
these documents is on average lower.
However, there is no homogeneity in coverage of the topics even
within one group of issues. After the detailed topic-specific analysis of
the documents it was found that the most covered topics are: protection
of human subjects (including informed consent issues, and ethical
considerations on genetic testing); genetic discrimination (including
genetic discrimination at work place); privacy and confidentiality
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Table 2. Policy issues in the genome sciences. 
Research issues
Prioritisation of research areas of funds
Provision of the necessary facilities/ quality control
Access to tools and research samples/ biobanking
Legal issues
Protection of human subjects
Regulatory oversight/ division of liabilities
Intellectual property and licensing practices
Genetic discrimination
Trade agreements
Privacy and confidentiality
Economic issues
Cost-effectiveness
Reimbursement of healthcare providers 
Market value and pricing
Supply and demand
Commercialization of the research findings
Education issues
Education of health professionals
Development of clinical guidelines
Classroom education
Public education/ PR actions
Risk communication
Acceptance and implementation issues
Public adoption of genomic technology
Behaviour modification in response to genomic results
Cultural respect
Figure 2. Study selection. Identification and selection of the doc-
uments.
Figure 3. Coverage of important areas of genomic sciences for
healthcare by international policy evidence. 
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(including genetic counselling); provision of the necessary facilities
(in respect of ensuring quality of the provided genetic tests and screen-
ings); access to tools, data and research samples (in respect of protec-
tion of human samples and organization of biobanks)
Analysis showed that the following important policy issues were vir-
tually not covered in the international guidelines: trade agreements
(including defining the role of the Pharmaceutical Companies); reim-
bursement of health-care providers by insurers and governments; pub-
lic adoption of genomic technology; behaviour modification in response
to genomic results; cultural aspects (except the non-discrimination on
the national base)
The majority of the collected evidence is dealing with the genetic
screening and genetic testing, i.e. genetic services in healthcare,
rather than the introduction of genome-based information and tech-
nologies into Public Health, i.e. Public Health Genomics including
genetic services. Out of 102 documents 61 were dealing with genetic
screening and testing, which was clearly stated in their title. The
main concern of the majority of these guidelines was safety of the
human subjects: physical and psychological. The importance of the
protection and safety of the human subjects cannot be contested.
However, from the broader Public Health Genomics perspective a sit-
uation in which focussing only on ethical genetic issues and concerns
is drawing attention away from other important considerations
should be avoided. 
In the final list, 22 guidelines represent mainly the provision of med-
ical services in general. These documents do not directly relate to pro-
vision of services including genetic/genomic information. Nevert -
heless, it was admitted by the experts that such guidelines can link the
gap between basic science and public policy reality, since these docu-
ments deal with patient-centred healthcare and public participation,
patient safety, Public Health innovations and property rights.
A lot of attention was paid to clinical validity and clinical utility of
genetic screening and genetic testing of human subjects. In other
words, many existing documents focus on the decision criteria which
define utility and reliability of the proposed genetic intervention. In the
present discussion in European health policy-making the main criteria
for the policy-makers and decision-makers is the impact of genome-
based information on the population health. However, such criteria can
be contested in the future due to the current paradigm shift from
(stratified) population utility and validity towards more personal utili-
ty and validity. Furthermore, one of the most important limitations of
the existing evidence is the fact that they focus mainly on the innova-
tions with (mono)genetic focus, leaving aside the high variety of other
-omic domains: i.e. pharmacogenomics, epigenomics, proteomics.
In general, a substantial difference in speed can be observed
between the development of genome-based basic sciences and Public
Health policies. This can partially be explained by the difficulty to
assess these health innovations, which are intended to be used in
Public Health, and the time needed for taking the necessary actions.
The present approach to the introduction of the new technologies into
Public Health is based on the translation of one size fits all interven-
tions through proving their positive impact on population health, i.e. to
as many as possible citizens. However, the traditional tools for the
assessment of technologies do not seem to work in the area of genome-
based information and technologies anymore and need to be adopted,18
which can contribute to the slowing down the introduction of genome-
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Table 3. Division of tasks in Public Health Genomics (adapted from Beskow et al., 20015).
Task Description Related essential tasks
Assessment The regular systematic collection, assembly, 1. Epidemiologic and laboratory research: quantifying the impact of gene variants on
analysis and dissemination of information, human health and identifying and quantifying the impact on human health of 
including human genome epidemiologic environmental risk factors that interact with gene variants.
information, on the health of the community. 2. Monitoring health: monitoring health status, including genetic factors, to identify
health problems within the community.
3. Diagnosing and investigating: investigating the distribution of genetic and
modifiable risk factors within the community to determine their contribution to
identify health problems and to improve health outcomes.
Policy development The formulation of standards and guidelines, 4. Epidemiologic and laboratory research: quantifying the impact of gene variants on
in collaboration with stakeholders, which promote human health and identifying and quantifying the impact on human health
the appropriate use of genetic information and of environmental risk factors that interact with gene variants.
the effectiveness, accessibility and quality of 5. Monitoring health: monitoring health status, including genetic factors,
genetic tests and services. to identify health problems within the community.
6. Diagnosing and investigating: investigating the distribution of genetic and
modifiable risk factors within the community to determine their contribution to
identify health problems and to improve health outcomes.
Assurance Assuring constituents that genetic information 7. Enforce laws: promoting the enforcement of policies and standards enacted
is used appropriately and that genetic tests and to ensure the appropriate use of genetic information and the effectiveness,
services meet agreed-upon goals for accessibility and quality of genetic tests and services.
effectiveness, accessibility and quality. 8. Link to/provide care: ensuring the availability and accessibility of genetic tests and
services and associated interventions to improve health and prevent disease.
9. Assure a competent workforce: ensuring that present and future health
professionals have training and skills in the appropriate use of genetic 
information to promote health and prevent disease.
10. Evaluate: evaluating the impact of genetic information and the effectiveness,
accessibility and quality of genetic tests and services.
System Building and maintaining the capacity of the
management public health infrastructure to integrate genomics
into public health research and practice.
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based innovations into Public Health. 
After the analysis of the collected policy evidence in Public Health
Genomics according to the Public Health Wheel (Table 2), the initial
hypothesis about the unequal distribution of evidence among the tasks
and processes in Public Health could be reconfirmed (Figure 4).
Although the priority is rightfully given to the safety and protection of
the human subjects, some other potentially important considerations,
such as reimbursement strategies, are missing.
The most covered area was Link to/Provide Care, which can be
explained by a high number of documents dealing with the issues of
protection of human subjects during the process of genetic
screening/test provision. Furthermore, the tasks of Diagnose and
Investigate together with Inform, Educate and Empower were frequent-
ly discussed. However, it should be noted that the medium relevance of
the documents dealing with education and empowerment is lower than
for the ones describing Link to/Provide Care and Diagnose and
Investigate. For instance, in the Inform, Educate and Empower, a lot of
attention was paid to the issues of education of the patients, rather
than social Health Literacy.
Among the areas in which substantial lack of guidance exists are:
mobilisation of community partnerships, which focuses on fostering
collaboration between public and private agencies and constituent
groups to promote effective and efficient communication and policy
making on genome-based information and technologies; process of
enforcement of the legal framework, promoting the enforcement of
policies and standards enacted to ensure the appropriate use of
genomic information the effectiveness, accessibility and quality of
genetic tests and services; assurance of competent workforce (includ-
ing the education and health literacy of health professionals) and
evaluation of the translation process; evaluation of the translational
process of genome-based information and technologies and its effec-
tiveness, efficiency and accessibility. On the other hand evidence
exists on the national levels about the quality of genetic tests and
services. However, there is still no unified approach to it; monitoring
health status to identify health problems within the community.
There is some evidence on the national and international level.19
However, the level of integration of genome-based information into
this evidence is very low. Out of 101 documents only 2 dealt with the
issue of using the genome-based information and technologies for
analyzing the health status of the people. 
Discussion
The present article summarizes the results of a mapping of the exist-
ing guidelines and best practice recommendations in the field of Public
Health Genomics on the international level, which had been carried out
by the Public Health Genomics European Network (PHGEN)
(www.phgen.eu). The analysis of the areas covered by these guidelines
showed that the issue of the introduction of the genome-based informa-
tion and technologies into the Public Health is unequally covered. There
is a considerable lack of guidelines addressing all of the Public Health
needs and perspectives. The main attention is paid nowadays to the eth-
ical and legal aspects of the use of genetic services rather than to the
translation of the prospective research inventions into Public Health.
While privacy and confidentiality issues were mentioned in a vast
majority of the analysed documents (which supports the view on protec-
tion of the subjects as highest priority), issues such as the allocation of
funds, trade agreements, cost-effectiveness, reimbursement of health-
care provision by insurers and governments, public adoption of genom-
ic technology are barely covered by any of the extracted documents.
Moreover, the existing guidelines focus on the genetic screening and
genetic testing aspects of genomics, which represent only a small part
of all the opportunities of the use of genome-based information. 
Due to the fact that the present research is the first and only
research, assessing policy evidence in the field of Public Health
Genomics, the initial literature search was of a very broad nature and
the assessment of the documents was done using consensus-based
method. The initial data set used during the analysis was not included
in the publication due to its size. Despite the relatively low number of
the experts participating in the assessment (n=35), the study involved
a multidisciplinary group of scientists from different fields linked to
Public Health Genomics (basic science, Public Health, medicine, law
etc.) thus having a wide area of topics covered. It is important to note
the absence of coherency in the terminology (i.e. genetic and genom-
ic), which was found during the assessment of the evidence, which
could potentially influence the results.
The potential limitations of the study include, firstly, the absence of
strict assessment criteria and the use of expert opinions and percep-
tions of the policy evidence in the field. Lately there is a lot of debate
in the literature regarding the validity and reliability of consensus-
based assessment for creation of the clinical guidelines in different
domains. In this study the consensus-based assessment was not used
for the clinical purposes.20 In the researched field of public policy-mak-
ing in Healthcare, public assessment methods, including experts, are
widely used for consultation purposes.21-23 Secondly, the research miss-
es the qualities of the systematic literature review, due to the fact that
the aim of the exercise was to provide initial mapping of the areas
presently covered by the international policy evidence, rather than
establishing the state of the art in the area of PHG. In the present arti-
cle the combination of the heterogeneous team and high level of agree-
ment in assessments given by the participants shows the value of such
practice-oriented evaluation for the future discussion on the policy and
regulation in the field of Public Health Genomics.
Based on the analysis of the collected evidence from the Public
Health perspective and its tasks and processes, it was revealed that
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Figure 4. Division of the existing international policy evidence in
Public Health Genomics, according to the major public health tasks.
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there is a considerable bias in the coverage. Because the process of
Public Health policy-making is ongoing, complex and interconnected,
such bias harms the evidence-base, quality and speed of the transla-
tional policy-making in the field of Public Health Genomics. In order to
create an integrative model for the translation of the outcome of
genome-based research into everyday Public Health practice a more
combinatory approach with elements of Public Health and public policy
is needed. The attention of policy-makers should cover different topics
within the field of Public Health Genomics (including health literacy,
insurance difficulties, trade and intellectual property issues etc.) and
some approaches from the social and public policy sciences can be ben-
eficial. One of the solutions might be cross-integration of the Public
Health Wheel (covering the sequence of tasks of Public Health) and the
blueprint for Public Health Genomics (identifying the area specific
points of focus). Such combination can be used as a map of important
areas that are to be cover legislatively in order to facilitate the assess-
ment and translation of genome innovations in the Public Health.
More research is needed focussing not only on the translation of
genome-based innovations into clinical practice, but also on the trans-
lation from bench to Public Health policy and back in order to secure
the continuous feedback loop to ensure quality. We suggest that a more
in-depth assessment of the quality of existing policy evidence should be
executed followed by the research on the needs of different stakehold-
ers that are to be incorporated in the policy decisions.
References
1. Burke W, Khoury MJ, Stewart A, Zimmern RL, Bellagio Group The
path from genome-based research to population health: develop-
ment of an international public health genomics network. Genet
Med 2006;8:451-8.
2. US Hears First Case of Genetic Discrimination. 2010 [Cited 15
June 2010]; Available from: http://legal-news.ashbycohen.co.uk/
discrimination/us-hears-first-case-of-genetic-discrimination/ 
3. Brand A. Public health genomics-public health goes personalized?
Eur J Public Health 2011;21:2-3.
4. Khoury MJ, Gwinn M, Burke W, Bowen S, Zimmern R. Will
genomics widen or help heal the schism between medicine and
public health? Am J Prev Med 2007;33:310-7.
5. Beskow LM, Khoury MJ, Baker TG, Thrasher JF. The integration of
genomics into public health research, policy and practice in the
United States. Community Genetics 2001;4:2-11.
6. [Anonymous]. Lost in clinical translation. Nat Med 2004;10:879.
7. Weinshilboum R, Wang L. Pharmacogenomics: bench to bedside.
Nat Rev Drug Discov 2004;3:739-48.
8. Woolf SH. The meaning of translational research and why it mat-
ters. JAMA 2008;299:211-3.
9. Kon AA. The Clinical and Translational Science Award (CTSA)
Consortium and the translational research model. Am J Bioeth
2008;8:58-60; discussion W1-3.
10. Marincola FM. Translational medicine: a two-way road. J Transl
Med 2003;1:1.
11. Brand A, Schröder P, Brand H, Zimmern R. Getting ready for the
future: integration of genomics into public health research, policy
and practice in Europe and globally. Public Health Genomi
2006;9:67-71.
12. Institute of Medicine of the National Academies. The Future of
Public Health. 1988, National Academy Press, Washington, DC,
USA.
13. Brand A, Brand H, Schulte in den Baumen T. The impact of genet-
ics and genomics on public health. Eur J Hum Genet 2007;16:5-13.
14. Galbraith C, Ehrlich S, DeNoble A. Predicting Technology success:
identifying key predictors and assessing expert evaluation for
advanced technologies. J Technol Transfer 2006;31:673-84.
15. Jones R, Flaherty EG, Binns HJ, Price LL, Slora E, Abney D, et al.
Clinicians description of factors influencing their reporting of sus-
pected child abuse: report of the child abuse reporting experience
study research group. Pediatrics 2008;122:259-66.
16. Haga SB, Willard HF. Defining the spectrum of genome policy. Nat
Rev Genet 2006;7):966-72.
17. Public Health in America. May 01, 2008. [Cited 05 November
2010]. Available from: http://www.health.gov/phfunctions/public.
htm
18. in den Baumen TS. Genome-based knowledge and public health:
the vision of tomorrow and the challenge of today. Eur J Public
Health 2011;21:4-5.
19. Nicklas W. International harmonization of health monitoring. ILAR
J 2008;49:338-46.
20. Pilling S. History, context, process, and rationale for the develop-
ment of clinical guidelines. Psychol Psychother 2008;81(Pt 4):331-
50.
21. Aurora RN, Morgenthaler TI. On the goodness of recommenda-
tions: the changing face of practice parameters. Sleep
2010;33:1273-6.
22. Van den Broucke S, Dargent G, Pletschette M. Development and
assessment of criteria to select projects for funding in the EU
health programme. Eur J Public Health 2011 (EPub ahead of print).
23. Lahtinen E, Koskinen-Ollonqvist P, Rouvinen-Wilenius P,
Tuominen P, Mittelmark MB. The development of quality criteria
for research: a Finnish approach. Health promotion international
2005;20:306-15.
Syurina et al.
Correspondence: Elena V. Syurina, Department of Social Medicine, School
for Public Health and Primary Care, Faculty of Health, Medicine and Life
Sciences, Maastricht University, Universiteitssingel 40 -West, 6229 ER
Maastricht, The Netherlands. Tel. +31.43.3882206 - Fax: +31.43.3881241. 
E-mail: e.syurina@maastrichtuniversity.nl
Key words: public health genomics, genomics, translational research, public
health, policy, legislation.
Acknowledgements: the authors thank the Public Health Genomics European
Network (PHGEN) for commissioning work on evidence analysis in Public
Health Genomics within the European Union. This work was supported by
two grants of the European Commission (DG SANCO, Agreement PHGEN I
No 2005313 and Agreement PHGEN II No 20081302). 
The helpful comments of E. Ambrosino are gratefully acknowledged. J.A. Lal
is acknowledged for the help in the initial development of the compilation of
evidence.
Contributions: EVS, data initial search, methodology choice, data analysis
and interpretation, manuscript drafting; TSB, data initial search, methodol-
ogy choice advice,  data assessment, initial text review;  FJMF,  article active
reviewing, advice on methodology and data integration, final approval; AB,
article initial idea and revision. 
Conflict of interest:  the authors report no conflict of interest.
Received for publication: 8 November 2011.
Accepted for publication: 5 January 2012.
©Copyright  E.V. Syurina et al., 2012
Licensee PAGEPress, Italy
Journal of Public Health Research 2012; 1:e8
doi:10.4081/jphr.2012.e8
This work is licensed under a Creative Commons Attribution NonCommercial
3.0 License (CC BY-NC 3.0).
No
n-c
om
me
rci
al 
us
e o
nly
